Two Sigma Advisers LP Lowers Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Two Sigma Advisers LP cut its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 28.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,300 shares of the medical instruments supplier's stock after selling 7,200 shares during the period. Two Sigma Advisers LP owned 0.08% of LeMaitre Vascular worth $1,686,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in LMAT. Smartleaf Asset Management LLC increased its position in shares of LeMaitre Vascular by 234.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 293 shares during the period. CBIZ Investment Advisory Services LLC grew its holdings in LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 117 shares during the period. KBC Group NV grew its holdings in LeMaitre Vascular by 58.4% during the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier's stock worth $102,000 after acquiring an additional 410 shares during the period. Huntington National Bank raised its position in shares of LeMaitre Vascular by 64.9% in the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock worth $107,000 after acquiring an additional 455 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of LeMaitre Vascular in the 4th quarter valued at about $150,000. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT traded up $1.10 during midday trading on Friday, hitting $82.17. 166,962 shares of the company's stock were exchanged, compared to its average volume of 168,628. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a market cap of $1.86 billion, a PE ratio of 44.90, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86. The stock has a 50 day moving average price of $83.86 and a 200-day moving average price of $91.72.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). The company had revenue of $59.87 million during the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period last year, the company earned $0.44 earnings per share. On average, analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date was Thursday, May 15th. LeMaitre Vascular's payout ratio is currently 40.40%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Lake Street Capital lifted their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective for the company. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular presently has a consensus rating of "Moderate Buy" and a consensus price target of $98.14.

Insider Buying and Selling

In related news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. This trade represents a 26.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO George W. Lemaitre sold 4,399 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total transaction of $374,354.90. Following the completion of the transaction, the chief executive officer now owns 1,827,003 shares in the company, valued at approximately $155,477,955.30. The trade was a 0.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 102,009 shares of company stock worth $8,721,836. 9.50% of the stock is owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.